Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNOT7 | Q9UIV1 | 7/20 | 0.43 |
| ▸ | PARN | O95453 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16028031 | 0.84 | CNOT7 (0.52) | CNOT7PARNLMNAMAPK1BRD4 | |
| SCHEMBL16076193 | 0.83 | CNOT7 (0.48) | CNOT7PARNLMNAMAPK1BRD4 | |
| SCHEMBL16079027 | 0.82 | LMNA (0.57) | LMNAMAPK1TRPA1NPC1TSHR | |
| SCHEMBL16076166 | 0.72 | LMNA (0.61) | CNOT7PARNLMNAMAPK1BRD4 | |
| SCHEMBL16079028 | 0.71 | MAPT (0.46) | LMNAMAPK1TSHRALDH1A1 | |
| SCHEMBL16027911 | 0.67 | LMNA (0.57) | CNOT7LMNAMAPK1TRPA1TSHR | |
| SCHEMBL2984842 | 0.66 | CNOT7 (0.54) | CNOT7PARNLMNABRD4BRD2 | |
| SCHEMBL14327687 | 0.65 | CNOT7 (0.53) | CNOT7PARNLMNAMAPK1TSHR | |
| SCHEMBL2993196 | 0.65 | CNOT7 (0.53) | CNOT7PARNLMNABRD4BRD2 | |
| SCHEMBL16079026 | 0.64 | SMN1; SMN2 (0.39) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20160237089-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | TRPC5, TRPC7, TRPC4 | CNOT7 1041/4885PARN 1953/4885LMNA 704/4885 |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | CNOT7 1041/4885PARN 1953/4885LMNA 704/4885 |
| US-20160237089-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | CNOT7 1041/4885PARN 1953/4885LMNA 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.